{"url_path":"/sec/spry/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1671858/0001193125-26-225142-index.html","accession_number":"0001193125-26-225142","cik":"0001671858","ticker":"SPRY","issuer_name":"ARS Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671858/0001193125-26-225142-index.html","primary_entity_key":"0001671858","primary_entity_name":"ARS Pharmaceuticals, Inc."},"word_count":371,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n[Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the registrant’s Annual Report on Form 10-K, filed with the SEC on March 23, 2023).](https://www.sec.gov/Archives/edgar/data/1671858/000095017023009491/spry-ex3_1.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K, filed with the SEC on December 8, 2020).](https://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex32.htm)\n\n10.1*‡\n\n \n\n[Second Amendment, dated March 5, 2026, to Co-Promotion Agreement, dated May 2, 2025 and first amended October 23, 2025, by and between ARS Pharmaceuticals, Inc. and ALK-Abelló Inc.](spry-ex10_1.htm)\n\n10.2*‡\n\n \n\n[First Amendment, dated March 11, 2026, to Supply Agreement, dated November 9, 2024, by and between ARS Pharmaceuticals, Inc. and ALK-Abelló A/S.](spry-ex10_2.htm)\n\n31.1\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](spry-ex31_1.htm)\n\n31.2\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](spry-ex31_2.htm)\n\n32.1\n\n[Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](spry-ex32_1.htm)\n\n101.INS\n\n \n\nInline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover page formatted as Inline XBRL and contained in Exhibit 101\n\n* Certain information in this exhibit is omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.\n\n‡ Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nARS PHARMACEUTICALS, INC.\n\n \n\n \n\n \n\n \n\nDate: May 15, 2026\n\n \n\nBy:\n\n/s/ Richard Lowenthal\n\n \n\n \n\n \n\nRichard Lowenthal, M.S., MSEL\n\n \n\n \n\n \n\nPresident and Chief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 15, 2026\n\n \n\nBy:\n\n/s/ Kathleen D. Scott\n\n \n\n \n\n \n\nKathleen D. Scott\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n106"}